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There is great interest in developing reliable biomarkers to support antemortem diagnosis of late-onset Alzheimer’s disease (AD).
Early prediction and diagnosis of AD might be improved by the detection of a proteolytic dysfunction in extracts from cultured
AD fibroblasts, producing altered isoelectrophoretic forms of the enzyme transketolase (TK-alkaline bands). The TK profile and
apolipoprotein E (APOE) genotype were examined in fibroblasts from 36 clinically diagnosed probable late-onset sporadic AD
patients and 38 of their asymptomatic relatives, 29 elderly healthy individuals, 12 neurological non-AD patients, and 5 early-onset
AD patients. TK alterations occurred in (i) several probable AD patients regardless of age-of-onset and severity of disease; (ii) all
early-onset AD patients and APOE 𝜀4/4 carriers; and (iii) nearly half of asymptomatic AD relatives. Normal subjects and non-AD
patients were all negative. Notably, culture conditions promotingTK alterationswere also effective in increasing active BACE1 levels.
Overall, the TK assay might represent a low-cost laboratory tool useful for supporting AD differential diagnosis and identifying
asymptomatic subjects who are at greater risk of AD and who should enter a follow-up study. Moreover, the cultured fibroblasts
were confirmed as a useful in vitromodel for further studies on the pathogenetic process of AD.
1. Introduction
A definite diagnosis of Alzheimer’s disease (AD) can be
accomplished only post-mortem by histopathology of the
autopsied brain so as to reveal amyloid beta protein (A𝛽)
in neuritic plaques and intraneuronal neurofibrillary tangles
[1, 2]. In past years several alterations in peripheral cells
and biological fluids of AD patients have been proposed as
potential antemortem AD biomarkers [3–6]. However, none
havemet the criteria established for an ideal biomarker [7, 8],
capable of assessing whether a mild cognitive impairment
(MCI)might reveal early stages of disease [9] or should rather
be linked to normal aging. In fact, advances in our knowledge
of AD have shown that symptoms usually develop after a
long preclinical pathogenetic process, making early detection
of AD in asymptomatic subjects of great interest. Indeed,
the assessment of presymptomatic subject cohorts regardless
of genetic predisposition [10, 11], including relatives of AD
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patients, could be highly useful in determining the effective-
ness of pharmacological intervention in slowing AD onset
and/or cognitive decline in AD patients.
Clinical criteria for AD diagnosis have recently been
revised [12] and the terms possible and probable AD have
been redefined by including some biomarkers for the patho-
physiological process in support of AD diagnosis. However,
their use has been limited to research settings due to the fact
that these procedures are not easily available to all patients.
The combination of multiple parameters [5, 13] obtained
through neuropsychological testing and conventional and
functional imaging [14, 15], together with the relatively low
accuracy attainable in discriminating AD from other demen-
tia [15], requires elaborate, serial, and costly procedures,
available only in the best academic centers and for a limited
number of patients. Therefore, there is a great need of
reliable and low-cost peripheral markers to identify persons
with incipient AD and complement clinical AD outcomes
in a large number of subjects. The National Institute on
Aging and Alzheimer’s Association international workgroup
recently reviewed the state-of-the-art in this field to develop
recommendations to determinewhich factors best predict the
risk of progression from “normal” cognition tomild cognitive
impairment (MCI) and AD dementia [16]. A combination
of CSF T-tau and A𝛽42/P-tau ratio has shown to be useful
for defining MCI patients at high risk of developing AD,
yielding a positive predictive value of 81% [17]. The various
constituents of blood, including plasma, platelets, and cellular
fractions [18], are now being systematically explored as a
pool of putative peripheral biomarkers for AD for the ease
of sampling and repeatability of measures [15, 19]. In this
context, disease-specific autoantibody profiles [20], increased
glutaminyl cyclase expression [21], and angiopoietin-1 levels
[22]have also been described in human sera. On the whole,
all these findings need verification in further studies [23, 24];
nevertheless they lend further support to the hypothesis that
AD patients suffer from a systemic metabolic dysfunction
that, in addition to the brain, also affects peripheral tissues.
Fibroblasts have also often been employed as an in
vitro model for neurological diseases [26] and, particularly,
for AD [4, 25, 27]. For instance, AD fibroblasts, unlike
their normal counterpart, display a variety of alterations
related to GM1 ganglioside catabolism [28], the function of
K+ channel [29] and Ca++ homeostasis [30], Erk1/2 levels
in response to bradykinin [6], cholesterol ester cycle [31],
and, eventually, dysregulated proteolysis [32–36]. Recently, a
fibroblast biomarker profile was proposed to identify accu-
rately AD patients for therapeutic intervention [37]. A very
attractive approach could be that of using patient fibroblasts
reprogrammed to neurons and exhibitingADphenotype [38]
as a model.
Herein, we report that early prediction and diagnosis
of AD might be improved by measuring typical proteolytic
alterations that we formerly found in cultured AD fibroblasts
[25].These alterations involve transketolase (TK), a thiamine-
dependent enzyme that undergoes limited degradation by
the enhanced activities of cysteine proteinases released upon
cell extraction [32, 33], to yield isoforms with unusually high
alkaline pI (TK-alkaline bands, TK-ab).
In this paper, for the first time subjects from 36 families
of probable late-onset AD patients were analyzed for the
frequency and intensity of the TK-ab signal, and for the
APOE genetic asset. Then, statistic analyses were carried
out to correlate TK-ab positivity and the presence of APOE
𝜀4 allele. Remarkably, asymptomatic first-degree relatives
were recruited and identified as subjects at greater risk of
developing AD [39], independently of their APOE genetic
asset.
These subjects are often overlooked in most studies
focused on detection of disease biomarkers without consider-
ing that AD relatives would probably be themost cooperative
and interested individuals for investigation with noninvasive
analyses.
Healthy subjects, patients with other non-AD neu-
ropathologies, and early-onset AD patients were also ana-
lyzed. Our results reveal TK-ab as a steady indicator of
cultured AD fibroblasts, that is, associated significantly with
both late- and early-onset forms of AD regardless of age-
of-onset or stage of disease. It could also be of prognostic
value, helpful in assessing AD risk in single individuals and
applicable to asymptomatic relatives of AD patients and
APOE-𝜀4 carriers [40].
BACE1 is the key rate-limiting enzyme for the production
of the A𝛽 peptide and its activity has been found to increase
under starvation in vitro [41] and after energy inhibition
in APP transgenic mice [42]. The amount of active BACE1
increased significantly in extracts of cultured fibroblasts pos-
itive to the Tk-ab test, supporting the usefulness of cultured
fibroblasts as an excellent in vitro model for the study of the
pathogenetic process of AD.
2. Patients and Methods
2.1. Subjects. Individuals who entered the study have been
enrolled in the Geriatric Unit of Prato Hospital (Italy) and
included (a) elderly healthy subjects (controls, 𝑛 = 29, mean
age ± SD = 66.8 ± 11.1, age range: 50–86); (b) patients
with a clinical diagnosis of probable late-onset or sporadic
AD (𝑛 = 36, mean age ± SD = 70.8 ± 7.3, age range: 61–
86); (c) asymptomatic first-degree relatives of AD patients
(𝑛 = 38, mean age ± SD = 46.7 ± 10.9, age range: 32–
68); and (d) neurological non-AD patients (𝑛 = 12, mean
age ± SD = 67.2 ± 10.5, age range: 50–84) including 4
patients with vascular dementia, 3 patients with frontotem-
poral dementia, 2 patients with Parkinson’s disease, 1 patient
with severe neurosis, 1 patient with intermittent ataxia, and
1 patient with olivopontocerebellar ataxia. Clinical diagnosis
of probable AD was made according to the criteria estab-
lished by the Diagnostic and Statistical Manual of Mental
Disorders (4th edition, DSM IV) [43], the National Institute
of Neurological and Communicative Disorders and Stroke,
and the Alzheimer’s Disease and Related Disorders Associ-
ation (NINCDSADRDA) [44] and reevaluated according to
the NIA-Alzheimer’s Association workgroups on diagnostic
guidelines for AD [12]. Medical examinations by neurologists
with the aid of neuropsychological and laboratory tests and
sometimes computed tomography or magnetic resonance of
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the brain were performed. The mini-mental state examina-
tion (MMSE) [45] and global deterioration scale (GDS) [46]
were used as the staging systems. Informedwritten consent to
use blood and dermal cells for analysis was obtained from the
subjects or, when necessary, from their legal guardians under
local institutional review board supervision and approval.
Further, we analyzed fibroblasts (kindly provided by S. Sorbi,
Department of Neurology, University of Florence) from
early-onset AD patients (𝑛 = 5, mean age ± SD = 48.0 ± 6.9,
age range: 38–55) carrying mutations of APP (Val717Ile, 1
case), presenilin 1 (PS1) (Met146Leu, 2 cases), and presenilin
2 (PS2) (Met239Val, 2 cases).
2.2. Skin Biopsies, Fibroblast Cultures, and Immunodetection of
TK-Isoforms. Skin biopsies were obtained from the forearm
of subjects by a 2mm punch, under local anesthesia with
2% xylocaine; healing was usually complete within a week.
Tissue fragments were placed in culture and fibroblasts were
then propagated under culture conditions favoring TK-ab
expression. Briefly, cells were seeded using a medium at pH
7.8 [47] andmaintained for 2 weeks without medium changes
[32]. Then fibroblasts were harvested and lysed by sonication
and cell extracts were separated by isoelectric focusing
(IEF) as previously reported [33]. Separated proteins were
transferred to a nitrocellulose membrane and then probed
with rabbit polyclonal IgG raised against humanTK [48]. TK-
isoforms were detected by either carbazole staining (Sigma,
St. Louis, MO) or ECL procedure (Amersham Biosciences)
[25, 33] and quantified by densitometric analysis with the aid
of ImageJ software (see Section 3 and legend in Figure 1).
2.3. APOE Genotyping. Peripheral blood mononuclear cells
were isolated by centrifugation at 1,700 g on Lymphoprep
(Eurobio, Les Ulis Cedex B, France). Genomic DNA was
then extracted by using theNucleoSpin Tissue kit (Macherey-
Nagel Gmbh & Co. KG, Du¨ren, Germany). DNA was ampli-
fied by PCR in aDNA thermal cycler (GeneAmp PCR System
2700, Applied Biosystems, NJ) as reported by Hixson and
Vernier [49].
2.4. BACE1 Determination. Fibroblasts from two healthy
aging control subjects (Cont 1 and Cont 2), from six probable
AD patients (AD1-6), and from two asymptomatic first-grade
AD relatives (Rel 1 and Rel 2) were analyzed. Cells were
seeded and maintained in parallel under conditions favoring
TK-ab production (see above), called “positive,” and under
normal conditions (with normal medium pH and detached
at confluence), called “negative.” Harvested fibroblasts were
extracted with RIPA buffer (R0278, Sigma, 0.1mL/1,000,000
cells) and protein concentration was assessed by the bicin-
choninic acid protein determination kit (Sigma). For BACE1
determination, aliquots (20 𝜇g) of total cell extracts were
separated on 4–12% NuPAGE Bis-Tris Gels with MOPS-
SDS running buffer (Novex, Invitrogen, Carlsbad, CA) and
blots were probed with anti-BACE1 antibody (NB120-10716,
Novus Biologicals, Littleton, CO). After incubation with
HRP-conjugated secondary antibodies, specific bands cor-
responding to BACE1 proteins were detected by the ECL
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Figure 1: The most representative typical and altered isoelec-
trophoretic (IEF) profiles of TK from cultured human fibroblasts. (a)
Aliquots (30–40 𝜇L; 1mg/mL) of fibroblast extracts were prepared
and separated by IEF within a pH range of 3–10 and then blots
were probed with anti-human TK antibody (see Section 2 and [25]).
Negative samples presented no distinct band or just a faint signal
over pH 8.4, while positive samples exhibited one to three heavily
stained TK-ab isoforms migrating toward the alkaline region of gel
(pH range of 8.5–9.4). (b) Densitometric analysis of immunostained
TK was carried out with the aid of the ImageJ software and values of
intensity were expressed as arbitrary units; the ratio between values
of TK-ab (pH ≥ 8.5) and those of the normal TK band (pH = 8.4) for
each sample is reported. The border between negative and positive
samples was arbitrarily set at a ratio of 0.4. TK, transketolase.
procedure (Amersham, Freiburg, Germany) and quantified
by densitometric analysis with the aid of ImageJ software.
Anti-GAPDH antibodies (Cell Signaling, Beverly, MA) were
used for detection of the housekeeping protein.
2.5. Statistics. TK-ab expression and APOE genotype fre-
quencies in different groups of subjects were compared by
means of Fisher’s exact test. The analysis of variance test
(ANOVA) was used to establish whether the degree of AD
severity or patient age differed significantly between TK-ab-
positive and -negative cases. Significance level was set at 𝑃 =
0.05. Sensitivity, specificity, accuracy, and predictive values
(PV) of TK-ab expression were reported together with 95%
confidence intervals (CI).
3. Results and Discussion
3.1. TK Analysis in Cultured Fibroblasts from Different Groups
of Subjects. Altered TK-isoforms (TK-ab) have frequently
been observed in extracts of cultured fibroblasts from AD
patients and proposed as potential indicators of disease
(see Section 1 and [25, 32, 34]). The conditions for optimal
expression and detection of TK-ab following IEF separation
have been reported elsewhere [32, 47]; however, for the
sake of clarity, a panel of the typical and of the most
representative altered TK profiles as well as the densitometric
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criteria used to evaluate results of the analysis were reported
(Figures 1(a) and 1(b), resp.). The protein band migrating
at pH 8.4 was the major TK isoform in control samples,
together with at least three minor and less basic bands.
Instead, TK-ab exhibited a more alkaline pI and migrated
within a pH range of 8.5–9.4. The presence of TK-ab was
usually assessed by visual inspection; however, to decide on
uncertain cases a densitometric analysis of immunostained
bands was employed. Intensity values of TK-ab (pH ≥ 8.5)
were calculated and divided by those of the normal TK band
(pH = 8.4); the border between negative and positive samples
was arbitrarily set at a ratio of 0.4. Of note, a strong positive
TK-ab signal (pH ≥ 8.5) as observed for many of the AD
patients was usually accompanied by a decrease in size and
staining of the major TK band (pH = 8.4).
TK profiles were analyzed in fibroblasts derived from
5 distinct groups of individuals and results are reported in
Figure 2 (for details see legend and Section 2).The number of
TK-ab-positive cases wasmarkedly high among probable AD
patients while both healthy controls and neurological non-
AD patients (neurol. controls) were all TK-ab negative. Based
on these findings, TK-ab could be validated as a potential
peripheral AD signature, showing a sensitivity = 69.4% (CI
= 51.9–83.6), a specificity = 100% (CI = 91.4–100), and an
accuracy = 85.7% (CI = 75.9–92.6). The negative or positive
predictive value (PV) was 78.8% (CI = 65.3–88.9) or 100%
(CI = 86.3–100), respectively. TK-ab-positive and -negative
cases did not differ significantly with regard to age-at-onset
(analysis of variance: 𝑃 = 0.76) or disease severity as
determined by GDS [46] and MMSE [45] clinical tests (𝑃 =
0.20 and 𝑃 = 0.26, resp.). Notably, early-onset AD patients
(dominant AD) carrying APP, PS1, and PS2 mutations were
all TK-ab positive. Nearly half (47.4%) of asymptomatic
first-degree AD relatives (mean age <50) turned out to be
TK-ab-positive. There was a striking statistically significant
difference in TK-ab expression in either possible AD patients
or AD relatives (𝑃 < 0.0005 for both subsets) versus healthy
controls. This result indicated a clear inclination of AD
relatives toward the distribution pattern of AD patients and
supported the view that individuals who have had an AD
patient in the family run a major risk of developing AD [39].
In particular, we found the percentage of TK-ab positivity in
our group of relatives at a level very near to that expected
for the dominantly inherited AD [50]. In this regard, our
cohort of patients had only a clinical diagnosis of probable
late-onset or sporadic AD, but we are inclined to exclude the
presence of inherited dominant mutations in relatives, given
the high level of age-at-onset of the disease (age range 65–
82) in patients.TheTK-ab positive relatives could conceivably
have a predisposing genetic and/or environmental asset; this
might require further analyses.
3.2. Cross-Evaluation of TK-ab Expression and APOE Geno-
type. Although our sample size is small, we have attempted to
establish whether the APOE-𝜀4 genotype, a well-known risk
factor for AD, was potentially related to TK-ab expression.
The answer to this question is negative; no statistically
significant correlation was found between TK-ab expression
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Figure 2: TK-ab determination in cultured dermal fibroblasts. Total
protein extracts from 29 healthy control subjects, 12 neurological
non-AD patients (neurol controls), 36 probable AD patients, 5
early-onset (dominant AD) patients, and 38 first-degree relatives
of AD patients (AD relatives) were analysed for TK-ab expression
as described in Figure 1. TK-ab-negative and -positive cases are
represented by open and closed circles, respectively.
and APOE genotype in either AD relatives or AD patients
(𝑃 = 0.746 and 𝑃 = 0.159, resp.) which would infer that these
parameters address distinct pathogenetic mechanisms.
3.3. Cross-Evaluation of TK-ab Expression and APOE Geno-
type in AD Relatives. The cross-evaluation of TK-ab positiv-
ity andAPOEgenotypewas carried outwithinAD relatives to
assess whether it might improve AD prediction within these
relatively young and asymptomatic subjects. Results showed
that the two homozygous 𝜀4/4 carriers were both TK-ab-
positive. Among heterozygous 𝜀3/4 carriers there were 5 out
of 10 TK-ab-positive cases; finally, TK-ab-positive cases were
highly represented among 𝜀3/3 (11 out of 21) and also one 𝜀2/3
carrier was positive. An increased number of positive cases
within 𝜀3/3 relatives of AD patients could have been expected
[39], and TK-ab positivity did not improve the prediction of
AD risk based on 𝜀4 allele frequency [40] at the population
level, but itmight be crucial to identifying those subjects who,
although asymptomatic, express TK-ab at early ages and are,
conceivably, at higher risk of progressing to AD.
3.4. Application of the Combined APOE/TK-ab Tests to
Families of Probable AD Patients. The combined results of
the clinical diagnosis and genetic and biochemical tests in
members of 6 out of the 36 families examined are shown in
Figure 3, where each family is represented by a probable AD
patient and 2 to 3 relatives (R).
Family 1. (AD, female, 70 years, onset at 67; R1, female, 43
years; R2, male, 41 years) R2 son, for its positivity to TK-ab
test, could be considered at higher risk of AD, despite the fact
he had a more protective APOE genetic asset than R1.
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Figure 3: Combined APOE/TK-ab tests in 6 families of probable
AD patients. Combined results of the clinical diagnosis and genetic
and biochemical tests in members of 6 representative families, each
with a probable AD patient (square symbol) and 2 to 3 relatives (R).
TK-ab positivity corresponded to closed symbols. APOE genotypes
are indicated inside symbols.
Family 2. (AD, female, 74 years, onset at 72; R1, female, 71
years; R2, female, 70 years) represented by a possible AD
patient and two sisters: it was confirmed that 𝜀4/4 subjects
were always positive to the TK-ab test whether they were
clinically diagnosed as AD patients or still unrecognized as in
the case of R1who, due to 𝜀4/4 homozygosity, will conceivably
develop AD in subsequent years.
Family 3. (AD, female, 86 years, onset at 78; R1, male, 58 years;
R2, male, 54 years; R3, female, 50 years). All three sons were
TK-ab positive, indicating that the presence of the marker
was a constant trait in this family; evidently, the whole genetic
asset conferred the same risk related to altered proteolysis to
the three Rs irrespective of 𝜀4 allele frequency thatmight play
a role in determining the age of onset.
Family 4. (AD, female, 81 years, onset at 79; R1, female, 55
years; R2, male, 51 years; R3, male, 39 years). The positivity
to TK-ab test addressed R2 as the subject with highest
probability of developing late-onset AD, that in principle
should have been equally shared by the two sons (R2 and R3),
both carrying the APOE 𝜀3/4 genetic asset.
Family 5. (AD,male, 81 years, onset at 77; R1, female, 49 years;
R2, male, 53 years): as in family 4, our results indicate R2 as
the subject with the highest risk of developing late-onset AD.
Family 6. (AD, female, 67 years, onset at 66; R1, female, 40
years; R2, female, 36 years; R3, male, 34 years). The AD
patient, for both the APOE genetic asset and the absence
of Tk-ab trait, should be clinically reevaluated for other
neuropathologies; R2 seems to be the only subject with the
highest probability of developing late-onset AD irrespective
of the absence of 𝜀4 allele.
3.5. BACE1 Determination and Activity following Culture
Conditions Producing TK-ab Forms. BACE1 is the key rate-
limiting enzyme for the production of the A𝛽 peptide and
its activity has been found to increase under starvation in
vitro [41] and after energy inhibition in APP transgenic mice
[42]. In order to assess whether our fibroblast samples might
show other well-known ADmetabolic alterations, that could
be related to TK-ab or not, BACE1 activity was determined
in extracts of cultured fibroblasts which were maintained in
parallel under culture conditions “positive” and “negative” for
TK-ab production (see Section 2). The results of a prelimi-
nary experiment are shown in Figure 4: two healthy aging
control subjects (Cont 1 and Cont 2), two AD relatives (Rel 1
andRel 2), and 6 probableADpatients (AD1-6)were analyzed
for BACE1 electrophoretic pattern. Three immunoreactive
bands of BACE1 protein were detected (see insert): (i) one
indicated the precursor protein (immature BACE1, ∼50KDa)
and (ii) two forms corresponded to the glycosylated active
enzyme (mature BACE1, within the range of 70–80KDa)
[51, 52]. We found that the amount of the active enzyme
increased significantly under positive culture conditions in
comparison to negative ones (ratio > 1), in fibroblast extracts
which contemporarily yielded a positive Tk-ab signal.
4. Conclusions
We propose that the TK-ab test may be used as a peripheral
indicator of disease in fibroblasts from AD patients in this
study. The sensitivity of this test (as opposed to specificity,
accuracy, and predictive values) was not extraordinarily high
but it should be remembered that these individuals were
diagnosed as probable AD patients only by standard clinical
criteria. There are, however, some aspects concerning the
significance and applications of TK analysis that deserve
further comments.
First, the TK-ab signature seems to be independent
of age-of-onset, severity, and form of AD. Such a steady
expression from the early to the late clinical stages of disease is
a distinctive feature of TK-ab as compared to other peripheral
AD indicators. In fact, even A𝛽 peptides, the most sensitive
and direct hallmark of AD, increase in plasma of rare
dominant AD patients [53] but not in most common late-
onset AD patients [54] who actually show a decline in A𝛽-42
levels [9, 55].
Secondly, TK-ab could be detected even in the absence of
clinical signs such as in (i) approximately half of the subjects
younger than 50 who, irrespective of 𝜀4 frequency, have had
anADpatient in the family and run amajor risk of developing
AD later in life [39] and (ii) in asymptomatic 𝜀4/4 carriers
who have a high probability of developing AD with age [40].
The identification of the TK-ab signature in combinationwith
genetic profile in relatives of AD patients—but it might also
be worth for subjects with MCI or less clearly determined
cognitive deficits—could provide early recognition of at-risk
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Figure 4: BACE1 activation by fibroblast culture conditions. Fibrob-
lasts from two healthy aging control subjects (Cont 1 and Cont
2), from 6 probable AD patients (AD1-6), two of whom resulted
negative to the TK-ab test (AD5 and AD6), and from two AD
relatives (Rel 1 and Rel 2) were cultured under conditions favoring
TK-ab production (positive) and under normal conditions (nega-
tive).Three immunoreactive bands of BACE1 protein were detected,
corresponding to the precursor protein (inactive BACE1) (∼50KDa)
and to two glycosylated active enzyme forms (active BACE1, within
the range of 70–80KDa), as shown in the insert. BACE1 proteins
were quantified by densitometric analysis using GAPDH as the
housekeeping; then the ratio between protein amounts in positive
and negative culture conditionswas calculated and reported for each
subject.
subjects and allow targeted intervention to delay neurode-
generation. We cannot say that all asymptomatic individuals
with a single APOE 𝜀4 gene dose and positive for TK-ab will
necessarily develop the disease at advanced age but, at least, it
could be possible to identify those subjects who should enter
a follow-up study.
Thirdly, our results suggest that mechanisms underlying
TK-ab production and BACE1 activation might be related. In
addition, the fact that the amount of active BACE1 increased
significantly in extracts of cultured Tk-ab-positive fibroblasts
reinforces the specificity of our test.
On the whole, this study supports the usefulness of
cultured fibroblasts as an excellent in vitromodel for the study
of the pathogenetic process of AD and for preliminary tests
of toxicity and efficacy of agents capable of reestablishing
the control of intracellular proteolysis, including BACE1
activation.
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